紫杉醇联合顺铂治疗晚期食管癌的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Paclitaxel combined with Cisplatin in the treatment of advanced esophageal cancer.Methods Fifty-six patients with advanced esophageal cancer admitted to our hospital from January 2015 to November 2017 were divided into control group(n=28)and observation group(n=28)according to random number table method，the patients in the control group were given conventional treatment,while the observation group was treated with Paclitaxel conbined with Cisplatin,the total effective rate,mean survival time,tumor progression time,quality of life and the total incidence of adverse reactions were compared of patients between the two groups.Results The total effective rate in the observation group of patients was higher than that of the control group,the difference was statistically significant(P＜0.05).The mean survival time and tumor progression time in the observation group of patients were longer than those of the control group,the differences were statistically significant(P＜0.05).The score of quality of life in the observation group of patients was higher than that in the control group，the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion In the clinical treatment of advanced esophageal cancer,the combination of Paclitaxel and Cisplatin can not only improve the total effective rate,prolong the average survival time and tumor progression time,but also improve the quality of life of patients.It is worthy of promotion in clinical application.

Key words： Paclitaxel Cisplatin Advanced esophageal cancer Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Jian-yang

Cite this article:

ZHAO Jian-yang. Clinical efficacy of Paclitaxel combined with Cisplatin in the treatment of advanced esophageal cancer[J]. 中国当代医药, 2018, 25(30): 107-109.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I30/107

[1]	毛灵.紫杉醇联合顺铂化疗治疗晚期食管的效果及对患者生存期的影响评价[J].现代医学与健康研究电子杂志，2018，2（5）：54.
[2]	康兆君.食管癌术后放疗同步紫杉醇+奈达铂方案治疗效果研究[J].中国医学创新，2017，14（12）：32-36.
[3]	汪建，王兴远，周伟，等.紫杉醇联合顺铂治疗晚期食管患者的临床疗效[J].医疗装备，2017，30（9）：125-126.
[4]	宋宏扬，赵文婧，徐治芳.紫杉醇联合顺铂治疗晚期食管的临床效果分析[J].系统医学，2017，2（8）：109-111.
[5]	王志飞.紫杉醇联合顺铂用于38例晚期食管化疗治疗的临床效果分析[J].中外医学研究，2017，15（1）：23-24.
[6]	许小伟，郭彩茹，王琛琛，等.紫杉醇联合顺铂治疗食管的临床分析[J].中外医疗，2016，35（21）：129-130，135.
[7]	王玺卿.顺铂联合紫杉醇及榄香烯注射液治疗晚期食管的临床价值研究[J].北方药学，2016，13（4）：90-91.
[8]	刘银生，张清河，甘育林.晚期食管治疗中紫杉醇联合顺铂化疗方案的临床价值探析[J].当代医学，2016，22（3）：130-131.
[9]	郑天明，陈海林，安尼瓦尔·买买提.紫杉醇联合顺铂治疗晚期食管癌的临床效果分析[J].世界临床医学，2017，11（9）：16.
[10]	陈轩，李真斌.紫杉醇联合顺铂化疗治疗晚期食管的临床效果研究[J].当代医学，2015，21（33）：153-154.
[11]	杨毅，吴霞.紫杉醇联合顺铂治疗晚期食管的临床效果探究[J].中国农村卫生，2015（8）：29-30.
[12]	成拯.周剂量紫杉醇对不宜手术的局部晚期食管癌患者放疗增敏作用研究[J].中国医学创新，2017，14（8）：28-31.
[13]	易军.紫杉醇、奈达铂化疗序贯放疗用于晚期食管癌的临床效果观察[J].中国当代医药，2016，23（23）：72-74.
[14]	杨明磊，董彩军，杜学奎，等.紫杉醇联合顺铂治疗晚期食管的临床效果分析[J].中国医药导报，2013，10（27）：74-75，78.
[15]	黄柒彬，李鸣，齐同谦，等.紫杉醇联合顺铂治疗晚期食管的临床效果探究[J].内蒙古中医药，2013，32（14）：4，18.